C3 AI is a technology company specializing in artificial intelligence software for enterprise applications. Its core products include AI-driven analytics and predictive modeling tools designed to enhance operational efficiency across various industries. Major business segments encompass energy, healthcare, and financial services, with primary revenue sources stemming from software licenses, subscriptions, and professional services.
The investment profile of C3 AI leans towards growth investors, given its focus on innovative technology solutions and potential market expansion. However, the company's recent performance indicators suggest heightened risk, making it less suitable for conservative investors. The stock may appeal to those with a longer investment horizon who are willing to navigate volatility for potential future gains.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-27 | Hold | Sell | Weak fundamentals and negative momentum signal high risk. |
| 2026-06-19 | Sell | Hold | Weak fundamentals and high risk limit upside potential. |
| 2026-05-08 | — | Sell | scenario_deterioration |
| 2026-05-08 | Sell | Sell | scenario_deterioration |
| 2026-03-17 | Hold | Sell | scenario_deterioration |
| 2026-03-11 | Sell | Hold | Компания демонстрирует значительное снижение выручки и отрицательный EPS, что указывает на финансовые проблемы. Текущие тренды и высокая волатильность делают инвестиции в C3 AI рискованными. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-04 | UBS | Target Raised | 9 → 12 | 10.8132 |
| 2026-06-04 | Morgan Stanley | Target Raised | 6 → 7 | 10.71 |
| 2026-06-04 | Canaccord Genuity | Target Raised | 8 → 10 | 10.71 |
| 2026-05-13 | Canaccord Genuity | Target Raised | 7 → 8 | 8.79 |
| 2026-02-26 | BMO Capital | Target Lowered | — → 7 | 8.135 |
| 2026-02-26 | Gordon Haskett Capital Corporation | Target Lowered | — → 7 | 8.135 |
| 2026-02-26 | D.A. Davidson | Target Lowered | — → 7 | 8.18 |
| 2026-02-26 | Wolfe Research | Target Lowered | — → 6 | 8.145 |
| 2026-01-30 | Oppenheimer | Target Lowered | — → 10 | 12.26 |
| 2025-09-09 | Morgan Stanley | Target Lowered | 22 → 11 | 15.74 |
| 2025-09-04 | UBS | Target Lowered | 23 → 16 | 16.68 |
| 2025-08-12 | UBS | Rating Downgraded | — → 17 | 16.7899 |
